01—Abstract
Summary
Summary of the 10-K filed February 27, 2009. Cited figures are marked; the original filing is the authoritative source.
Boston Scientific Corporation's (BSX) 2008 10-K filing reveals a challenging year marked by a significant net loss primarily driven by substantial goodwill and intangible asset impairment charges totaling $2.79 billiona.
This impairment was largely attributed to the impact of disruptions in the credit and equity markets following the 2006 Guidant acquisition. Despite the net loss, the company generated robust operating cash flow of $1.216 billionb, demonstrating operational resilience. Net sales saw a slight decrease of 4% to $8.05 billion, impacted by increased competition in the drug-eluting stent market and the divestiture of non-strategic businesses.
However, growth was observed in the Cardiac Rhythm Management (CRM) segment, up 8%, and Endosurgery, up 8%, highlighting strategic product launches and market penetration. The company is actively managing its financial position by reducing debt, having prepaid $1.425 billionc under its term loan and credit facility in 2008. Furthermore, Boston Scientific is implementing cost-saving measures, including a plant network optimization plan aimed at simplifying manufacturing and improving gross margins.
The company's product portfolio remains strong, with continued investment in innovation for both CRM and cardiovascular devices. Key risks highlighted include intense competition, regulatory scrutiny, and the ongoing impact of economic downturns on healthcare spending and reimbursement.
02—Key points
Key Highlights
- Reported a net loss of $2.036 billion ($1.36 per share) for 2008, largely due to $2.79 billion in goodwill and intangible asset impairment charges.
- Generated positive cash flow from operations of $1.216 billion, indicating operational strength.
- Net sales decreased by 4% to $8.05 billion, primarily impacted by competitive pressures in the drug-eluting stent market.
- Cardiac Rhythm Management (CRM) sales increased by 8% to $2.286 billion, driven by new product launches.
- Divested several non-strategic businesses in early 2008, generating approximately $1.3 billion in proceeds and streamlining operations.
- The company reduced its total debt by $1.444 billion during 2008, bringing total debt to $6.745 billion.
- Ongoing litigation with Johnson & Johnson resulted in significant legal charges, with a $334 million charge recorded in 2008 related to a patent infringement ruling.
03—One dollar
Follow one dollar
For each $1.00 of revenue in FY2008, Boston Scientific Corp lost $0.25.
- Revenue$8.05B100.0%
- Cost of revenue−$2.47B30.7%
- Gross profit$5.58B69.3%
- Operating costs−$7.09B88.0%
- Operating income−$1.50B18.7%
- Interest, other & tax−$531.0M6.6%
- Net income−$2.04B25.3%
04—Financials
Financial Highlights
Figures from 10-KFY2008filed February 27, 2009Financial Statements
FY2008 against FY2007
| Line item | FY2008FY2007 | Change |
|---|---|---|
| Revenue | $8.05B$8.36B | −3.7% |
| Cost of Revenue | $2.47B$2.34B | +5.4% |
| Gross Profit | $5.58B$6.01B | −7.2% |
| SG&A Expenses | $2.59B$2.91B | −11.0% |
| Operating Expenses | $7.09B$6.03B | +17.5% |
| Operating Income | -$1.50B-$14.00M | −10650.0% |
| Interest Expense | $468.00M$570.00M | −17.9% |
| Net Income | -$2.04B-$495.00M | −311.3% |
| EPS (Basic) | $-1.36$-0.33 | −312.1% |
| EPS (Diluted) | $-1.36$-0.33 | −312.1% |
| Shares Outstanding (Basic) | 1.50B1.49B | +0.8% |
| Shares Outstanding (Diluted) | 1.50B1.49B | +0.8% |
05—Questions
Frequently Asked Questions
What was the primary driver of Boston Scientific's net loss in 2008?
The primary driver of Boston Scientific's net loss of $2.036 billion in 2008 was the significant goodwill and intangible asset impairment charges of $2.79 billion. This was largely a result of market disruptions and the impact of the 2006 Guidant acquisition on the company's market capitalization and cost of capital.
How did the company's sales performance vary across its business segments?
Sales performance varied by segment. The Cardiac Rhythm Management (CRM) segment showed strong growth with an 8% increase in net sales, driven by new product introductions like the COGNIS® and TELIGEN® systems. The Endosurgery segment also grew by 8%. However, the Cardiovascular division experienced a 4% decline in net sales, primarily due to increased competition in the drug-eluting stent market.
What is the company's debt situation and what steps are being taken to manage it?
As of December 31, 2008, Boston Scientific had $6.745 billion in total debt. The company actively managed its debt by prepaying $1.425 billion of its term loan and credit facility in 2008. This proactive debt management aims to improve its financial flexibility and reduce interest expenses.
What are the key risks facing Boston Scientific according to the 10-K filing?
Key risks highlighted include intense competition in its core markets (particularly drug-eluting stents and CRM), increasing regulatory scrutiny from bodies like the FDA, potential negative impacts from healthcare cost containment measures and reimbursement pressures, and the ongoing litigation, notably the significant patent dispute with Johnson & Johnson.
06—Continue